Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite

Michael Platten(University of Lisbon), Peggy P. Ho(University of Lisbon), Sawsan Youssef(University of Lisbon), Paulo Fontoura(University of Lisbon), Hideki Garren(University of Lisbon), Eun Mi Hur(University of Lisbon), Rohit Gupta(University of Lisbon), Lowen Y. Lee(University of Lisbon), Brian Kidd(University of Lisbon), William H. Robinson(University of Lisbon), Raymond A. Sobel(University of Lisbon), Michael L. Selley(University of Lisbon), Lawrence Steinman(University of Lisbon)
Science
November 3, 2005
Cited by 418

Abstract

Local catabolism of the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO) is considered an important mechanism of regulating T cell immunity. We show that IDO transcription was increased when myelin-specific T cells were stimulated with tolerogenic altered self-peptides. Catabolites of Trp suppressed proliferation of myelin-specific T cells and inhibited production of proinflammatory T helper-1 (T(H)1) cytokines. N-(3,4,-Dimethoxycinnamoyl) anthranilic acid (3,4-DAA), an orally active synthetic derivative of the Trp metabolite anthranilic acid, reversed paralysis in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS). Trp catabolites and their derivatives offer a new strategy for treating T(H)1-mediated autoimmune diseases such as MS.


Related Papers

No related papers found

Powered by citation graph analysis